Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 12INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Leukemia, Myeloid, Acute 3Breast Neoplasms 3Triple Negative Breast Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm, Residual 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × Anthracyclines × Clear all
NCT04109066 2025-01-08

CheckMate 7FL

Bristol-Myers Squibb

Phase 3 Completed
521 enrolled 17 charts
Breast

Breast Neoplasms, Neoplasms

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
126 enrolled 16 charts
Breast

Breast Neoplasms

NCT02561832 2019-02-20

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

AstraZeneca

Phase 1 Terminated
15 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡